These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15177425)

  • 21. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
    J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer.
    Chow LW; Yip AY; Lang BH
    Am J Clin Oncol; 2007 Apr; 30(2):133-8. PubMed ID: 17414461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The clinical efficacy of CAC regimen in the treatment of advanced breast cancer].
    Zhang P; Zhou J; Feng F
    Zhonghua Zhong Liu Za Zhi; 1995 Sep; 17(5):365-7. PubMed ID: 8697977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
    Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
    Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
    Saeki T; Okita A; Aogi K; Kakishita T; Okita R; Taira N; Ohama Y; Takashima S; Nishikawa K
    Breast Cancer; 2009; 16(2):113-20. PubMed ID: 18936884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer.
    Kaufman PA
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):39-46. PubMed ID: 10403473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
    Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
    Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
    Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
    Gennari A; Amadori D; De Lena M; Nanni O; Bruzzi P; Lorusso V; Manzione L; Conte PF
    J Clin Oncol; 2006 Aug; 24(24):3912-8. PubMed ID: 16921042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus.
    Zhang X; Shen L; Li J; Li Y; Li J; Jin M
    Am J Clin Oncol; 2008 Feb; 31(1):29-33. PubMed ID: 18376224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):192-3. PubMed ID: 12202899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
    Gogas H; Papadimitriou C; Kalofonos HP; Bafaloukos D; Fountzilas G; Tsavdaridis D; Anagnostopoulos A; Onyenadum A; Papakostas P; Economopoulos T; Christodoulou C; Kosmidis P; Markopoulos C
    Ann Oncol; 2002 Nov; 13(11):1737-42. PubMed ID: 12419745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin.
    Catino A; Crucitta E; Latorre A; Sambiasi D; Calabrese P; Lorusso V
    Oncol Rep; 2003; 10(1):163-7. PubMed ID: 12469164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
    Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
    Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical study of weekly paclitaxel administration for metastatic breast cancer based on time to progression (TTP) and survival].
    Emoto T; Yoshikawa K; Yoshioka Y; Nezu R; Fujikawa M; Fujii M; Maeda S; Naka Y; Komaki T
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):817-22. PubMed ID: 12852349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High efficacy of paclitaxel and doxorubicin as first-line therapy in advanced breast cancer: a phase I-II study.
    De Lena M; Latorre A; Calabrese P; Catino A; Lorusso V; Mazzei A; Aloe A
    J Chemother; 2000 Aug; 12(4):367-73. PubMed ID: 10949988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
    Booser DJ; Esteva FJ; Rivera E; Valero V; Esparza-Guerra L; Priebe W; Hortobagyi GN
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.